Souhaitez-vous accéder aux communiqués récents ?

Company announcement – No. 35 / 2020 Zealand Pharma announces completion of directed issue and private placement of 2,684,461 new ordinary shares              NOT FOR RELEASE, PUBLICATION OR...

Company announcement – No. 34 / 2020 Zealand Pharma announces directed issues and private placements of up to approx. 2.68 million new ordinary shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION...

Company announcement – No. 33 / 2020 Zealand Pharma strengthens executive team with new U.S. leadership Copenhagen, June 15, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....

Press release – No. 09 / 2020   Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association...

Press release – No. 08 / 2020 Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go® in older adults with type 2 diabetes, at the 80th Scientific Sessions...

Company announcement – No. 32 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, June 12, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ:...

Press Release – No. 07 / 2020 Zealand Pharma to leverage Intomics bioinformatics platform within peptide drug discovery and development process The research agreement enhances Zealand Pharma’s...

Press release – No. 06 / 2020 Zealand Pharma to attend Jefferies and Goldman Sachs Virtual Healthcare Conferences Copenhagen, June 1, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology...

Company announcement – No. 31 / 2020 Total number of shares and voting rights in Zealand Pharma at May 31, 2020 Copenhagen, May 29, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20...

Company announcement – No. 30 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...